EBS:VIEErste Group Bank AG Analysis

Emergent BioSolutions (EBS) trades around $8.32, well below its 20‑day SMA of $8.38 and the 50‑day SMA of $8.41, indicating short‑term weakness. The 200‑day SMA sits near $9.72, reinforcing a bearish technical landscape, while the MACD histogram remains negative and the RSI hovers at 48.7, suggesting limited upside momentum in the near term. Volatility is elevated at 56.8% over the past 30 days and beta is 1.57**, underscoring heightened price swings relative to the market. Despite these pressures, the company’s DCF fair value of roughly $57.5 implies a massive valuation gap, translating to a projected upside of over 44% from current levels. Recent material news shows the firm securing a Saudi contract, receiving Health Sciences Authority approval for expanded ACAM2000 use, and winning additional government contracts, which could bolster revenue and mitigate the recent –29.7% revenue decline. The forward EPS of $2.99 and a forward PE of 2.78 further highlight the potential for earnings recovery once new contracts ramp up.
From a fundamentals perspective, EBS carries a low price‑to‑book of 0.82 and a price‑to‑sales of 0.63, but it remains loss‑making on a trailing basis (negative EPS) with a modest operating margin of 6.8% and a negative profit margin. The balance sheet shows $160M cash against $585M debt, yielding a high debt‑to‑equity ratio, yet operating cash flow of $148M and free cash flow of $256M indicate sufficient liquidity to fund near‑term operations. The combination of deep undervaluation, pipeline approvals, and new contract wins suggests a longer‑term rebound, while short‑term price action may stay constrained by bearish technical signals and elevated risk.